Side-by-side · Research reference
ProstamaxvsTestagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED11/38 cited
BAnimal-MechanisticHUMAN-REVIEWED11/41 cited
Prostamax
Khavinson Bioregulator · Tissue-Specific Peptide
4 AAPeptide length
SQ · Protocol per Khavinson tradition
Testagen
Bioregulator Peptide · Khavinson School
SQ · Abdomen · Cyclical
01Mechanism of Action
Parameter
Prostamax
Testagen
Primary target
Chromatin in prostatic cells — pericentromeric heterochromatin regions
Testicular tissue; proposed nuclear DNA interaction
Pathway
Epigenetic modulation → heterochromatin decondensation → transcriptional derepressionDzhokhadze 2012
Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011
Downstream effect
Increased sister chromatid exchange, Ag-NOR activation, reduced C-heterochromatin condensation; tissue-specific regenerative stimulation in prostate organotypic culturesDzhokhadze 2012Zakutskiĭ 2006
Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011
Feedback intact?
—
Unknown — no HPG axis data
Origin
Synthetic tetrapeptide modeled on naturally occurring protein-derived bioregulators isolated between lysine-arginine motifs in long-lived speciesKhavinson 2017
Khavinson bioregulator school — isolated from testicular tissue peptide fractions
Antibody development
—
—
02Dosage Protocols
Parameter
Prostamax
Testagen
Effective concentration (in vitro)
0.05 ng/mLZakutskiĭ 2006
Organotypic culture model; demonstrated tissue-specific stimulation.
—
Human clinical dose
Not established
No published human trials; dosing extrapolated from Russian clinical tradition (not peer-reviewed).
—
Evidence basis
Animal / organotypic cultureZakutskiĭ 2006Dzhokhadze 2012
No randomized controlled trials in humans.
Animal mechanistic / in vitro onlyFedoreyeva 2011
Age groups studied
Young (3-week) and aged (18-month) rats; elderly humans (75–86 years) in vitroZakutskiĭ 2006Dzhokhadze 2012
—
Duration
Not specified
Khavinson protocols typically 10–20 days per cycle; no long-term safety data.
—
Typical protocol (anecdotal)
—
100–200 mcg / day
No published human dosing studies; derived from Russian bioregulator practice.
Frequency
—
Once daily or alternate days
Cycle length
—
10–20 days on, 10–14 days off
Bioregulator tradition uses pulsed cycles; no controlled data.
Route
—
Subcutaneous
Reconstitution
—
Sterile water or bacteriostatic saline
Half-life
—
Unknown — likely minutes (short peptide)
04Side Effects & Safety
Parameter
Prostamax
Testagen
Published adverse events
None reported in available literature
—
Genotoxicity signals
Increased sister chromatid exchange (SCE) — marker of DNA recombination/repair; unclear long-term implications
—
Metal ion interactions
Modulates Cu(II) and Cd(II) chromatin effects; unknown clinical relevance
—
Human safety data
Absent — no published Phase 1/2/3 trials
—
Injection site reactions
—
Erythema, mild irritation (potential)
Systemic effects
—
Unknown — no human safety data
Hormonal impact
—
No published data on testosterone, LH, FSH effects
Long-term safety
—
Unknown — no long-term studies
Absolute Contraindications
Prostamax
- ·Active prostate malignancy — epigenetic modulation effects unknown in cancer
Testagen
- ·Active testicular malignancy
Relative Contraindications
Prostamax
- ·History of prostate cancer — theoretical concern re: transcriptional activation
- ·Undiagnosed prostatic nodules or elevated PSA
Testagen
- ·Hormone-sensitive cancers (no data; theoretical caution)
- ·Pregnant or breastfeeding (no data)
05Administration Protocol
Parameter
Prostamax
Testagen
1. Route
Subcutaneous or intramuscular — per Khavinson bioregulator tradition. No published human pharmacokinetic data.
Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.
2. Reconstitution
If lyophilised: reconstitute with sterile water per manufacturer protocol (not standardized in literature).
Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).
3. Frequency
Typically daily or every-other-day in Russian clinical tradition; duration 10–20 days per cycle.
Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.
4. Monitoring
No established biomarkers. Theoretical: PSA, prostate imaging, symptom scores (IPSS for BPH).
Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.
5. Note
All protocols derived from non-peer-reviewed Russian clinical practice; Western regulatory approval absent.
10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.